Rezolute, Inc. Files 8-K

Ticker: RZLT · Form: 8-K · Filed: Aug 5, 2024 · CIK: 1509261

Rezolute, Inc. 8-K Filing Summary
FieldDetail
CompanyRezolute, Inc. (RZLT)
Form Type8-K
Filed DateAug 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: disclosure, regulatory

TL;DR

Rezolute filed a standard 8-K, no major news.

AI Summary

Rezolute, Inc. filed an 8-K on August 5, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as AntriaBio, Inc., is incorporated in Nevada and headquartered in Redwood City, California. This filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a standard disclosure for Rezolute, Inc., informing the public about regulatory compliance and financial reporting, which is crucial for investor transparency.

Risk Assessment

Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events or financial information that would indicate increased risk.

Key Players & Entities

  • Rezolute, Inc. (company) — Registrant
  • AntriaBio, Inc. (company) — Former company name
  • August 5, 2024 (date) — Date of report
  • Nevada (jurisdiction) — State of incorporation
  • Redwood City, CA (location) — Principal executive offices

FAQ

What is the primary purpose of this 8-K filing for Rezolute, Inc.?

The primary purpose of this 8-K filing is for Regulation FD Disclosure and to report Financial Statements and Exhibits.

When was this 8-K report filed?

This 8-K report was filed on August 5, 2024.

What was Rezolute, Inc. formerly known as?

Rezolute, Inc. was formerly known as AntriaBio, Inc.

In which state is Rezolute, Inc. incorporated?

Rezolute, Inc. is incorporated in Nevada.

Where are Rezolute, Inc.'s principal executive offices located?

Rezolute, Inc.'s principal executive offices are located at 275 Shoreline Drive, Suite 500, Redwood City, CA 94065.

Filing Stats: 590 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-08-05 07:30:33

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share RZLT Nasdaq Capital Market

Filing Documents

01

Item 7.01 Regulation FD Disclosure. On August 5, 2024, Rezolute, Inc. (the "Company") issued a press release announcing clearance by the U.S. Food and Drug Administration for its Investigational New Drug application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism. Additionally on August 5, 2024, the Company made available an updated Corporate Presentation on the Investor Relations page of its website, which will be used at investor and other meetings. A copy of the press release and Corporate Presentation are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibits 99.1and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated August 5, 2024 99.2 August 2024 Corporate Presentation, dated August 5, 2024 104 Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REZOLUTE, INC. DATE: August 5, 2024 By: /s/Nevan Charles Elam Nevan Charles Elam Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.